StageAcq - P2P | Acquired
About CinCor Pharma
CinCor Pharma (NASDAQ: CINC) operates as a clinical-stage biopharmaceutical company. It focuses on developing a clinical candidate, baxdrostat, for the treatment of hypertension and other cardio-renal diseases. The company was founded in 2018 and is based in Cincinnati, Ohio. In February 2023, CinCor Pharma was acquired by AstraZeneca in the range of $1.3B to $1.8B.
Missing: CinCor Pharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: CinCor Pharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing CinCor Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
CinCor Pharma is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Latest CinCor Pharma News
Feb 28, 2023
AstraZeneca has closed the previously announced $1.8 billion acquisition of US biopharmaceutical company CinCor Pharma. Under the terms of the agreement, AstraZeneca acquired all outstanding shares as well as the cash and marketable securities of CinCor Pharma for approximately $1.3bn upfront and around $500 million, respectively. With the acquisition, AstraZeneca anticipates to increase its cardiorenal portfolio by adding baxdrostat (CIN-107), an aldosterone synthase inhibitor that lowers blood pressure in patients with resistant hypertension. Founded in 2018, CinCor Pharma develops new treatments for resistant and uncontrolled hypertension as well as chronic kidney disease. AstraZeneca closes $1.8bn acquisition of CinCor Pharma. Photo courtesy of AstraZeneca. CinCor Pharma’s lead asset baxdrostat (CIN-107) is in clinical development for the treatment of hypertension and primary aldosteronism. The transaction also brings the potential for combination with Farxiga and complements AstraZeneca’s strategy to provide added benefit across cardiorenal diseases. CinCor Pharma will soon stop trading on the Nasdaq and will terminate its registration under the US Securities Exchange Act of 1934 following completion of the acquisition. Centerview Partners served as exclusive financial advisor and Cooley acted as legal advisor to CinCor Pharma while Covington & Burling served as legal advisor to AstraZeneca in connection with the transaction. In 2023, AstraZeneca also completed the acquisition of Neogene Therapeutics , a next -generation T-cell receptor manufacturer, for an initial payment of $200m and an additional up to $120m contingent milestone-based and non-contingent consideration.
CinCor Pharma Frequently Asked Questions (FAQ)
When was CinCor Pharma founded?
CinCor Pharma was founded in 2018.
Where is CinCor Pharma's headquarters?
CinCor Pharma's headquarters is located at 230 Third Avenue, Waltham.
What is CinCor Pharma's latest funding round?
CinCor Pharma's latest funding round is Acq - P2P.
How much did CinCor Pharma raise?
CinCor Pharma raised a total of $193M.
Who are the investors of CinCor Pharma?
Investors of CinCor Pharma include AstraZeneca, Sofinnova Ventures, Sofinnova Partners, 5AM Ventures, Perceptive Advisors and 12 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.